← Leaderboards
Aiwu Ruth He
Georgetown University
$1,190,093
Attributed
$2,367,535
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $565.4K · FY2008–22$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,367,535 · 3
By mechanism
U01$2,354,885 · 1
M01$12,650 · 2
Top collaborators
- Fung-Lung Chung5 shared
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingMalignant NeoplasmsBaseDna AdductsDisorder Later Incidence PreventionCancer EtiologyDiagnosisAlcoholic Liver DiseasesBiological MarkersAcroleinAftercareBlood VesselsCessation Of LifeCancer RecurrenceCarcinogenesisBindingChemotherapyClinicClinical ApplicationClinical PredictorsBiopsy SpecimenAnimal ModelAntioxidantsAdduct
Grant awards (7)
gamma-OHPdG as a prognostic biomarker of HCC recurrence and its prevention$441,284
U01 · FY2022 · CA
gamma-OHPdG as a prognostic biomarker of HCC recurrence and its prevention$327,696
U01 · FY2021 · CA
gamma-OHPdG as a prognostic biomarker of HCC recurrence and its prevention$565,396
U01 · FY2020 · CA
gamma-OHPdG as a prognostic biomarker of HCC recurrence and its prevention$502,311
U01 · FY2019 · CA
gamma-OHPdG as a prognostic biomarker of HCC recurrence and its prevention$518,198
U01 · FY2018 · CA
PROTOCOL_TITLEPILOT STUDY OF TANDEM MASS SPECTROMETRY IN PATIENTS WITH GI MALI$11,222
M01 · FY2009 · RR · contact PI
PILOT STUDY OF TANDEM MASS SPECTROMETRY IN PATIENTS$1,428
M01 · FY2008 · RR · contact PI